BioXcel Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $214 | $1,104 | $582 | $376 |
Gross Profit | -956 | 1,042 | 424 | -416 |
EBITDA | -9,783 | -4,522 | -23,106 | -18,743 |
EBIT | -9,860 | -4,599 | -23,184 | -18,821 |
Net Income | -13,650 | -8,298 | -26,791 | -22,256 |
Net Change In Cash | 214 | 1,104 | 582 | 376 |
Free Cash Flow | -16,338 | -23,174 | -17,706 | -26,863 |
Cash | 40,387 | 56,271 | 74,141 | 65,221 |
Basic Shares | 42,390 | 40,253 | 30,868 | 29,449 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $1,380 | $375 | $0 | $ |
Gross Profit | 120 | 355 | -297 | |
EBITDA | -165,421 | -157,384 | -106,638 | -82,109 |
EBIT | -165,739 | -157,711 | -106,935 | -82,297 |
Net Income | -179,053 | -171,849 | -106,630 | -82,008 |
Net Change In Cash | 1,380 | 375 | 0 | |
Cost of Revenue | -39,243 | 19,849 | 180,693 | |
Free Cash Flow | -155,026 | -135,480 | -82,598 | -66,666 |
Cash | 65,221 | 193,725 | 232,968 | 213,119 |
Basic Shares | 29,129 | 28,015 | 26,373 | 21,683 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.32 |
2024-06-30 | -$0.21 |
2024-03-31 | -$0.87 |
2023-12-31 | -$0.76 |
